You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Claims for Patent: 6,939,559

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 6,939,559

Title:	Pharmaceutical composition for application to mucosa
Abstract:	The present invention provides a pharmaceutical composition for application to the mucosa to be used in drug therapy comprising a water-insoluble and/or water-low soluble substance, a medicament, and an aqueous medium, and having an osmotic pressure of less than 290 mOsm. This composition is superior over conventional pharmaceutical compositions for application to the mucosa, due to efficient and high permeability to the blood at the mucosa. The present invention further provides a pharmaceutical composition for application to the mucosa comprising a hemostatic agent and a medicament. This composition is superior over conventional pharmaceutical compositions for application to the mucosa, due to permeability and retentivity at the mucosa.
Inventor(s):	Nishibe; Yoshihisa (Hino, JP), Kinoshita; Wataru (Hino, JP), Kawabe; Hiroyuki (Tokyo, JP)
Assignee:	Teijin Limited (Osaka, JP)
Application Number:	09/446,276
Patent Claims:	1. An aqueous pharmaceutical composition for application to the mucosa, comprising one or more water-insoluble and/or low water soluble substance, and one or more medicament, and having an osmotic pressure of 72 mOsm or less. 2. A pharmaceutical composition for application to the mucosa, comprising one or more hemostatic agent and one or more medicament. 3. An aqueous pharmaceutical composition for application to the mucosa, comprising one or more hemostatic agent, one or more water-insoluble and/or low water soluble substance, and one or more medicament, and having an osmotic pressure of 72 mOsm or less. 4. The pharmaceutic composition for application to the mucosa according to claim 1 or 3, wherein said osmotic pressure is 60 mOsm or less. 5. The pharmaceutical composition for application to the mucosa according to claim 1 or 3, wherein said osmotic pressure is 30 mOsm or less. 6. The pharmaceutical composition for application to the mucosa according to claim 1 or 3, wherein said osmotic pressure is 10 mOsm or less. 7. The pharmaceutical composition for application to the mucosa according to claim 1 or 3, further comprising an osmotic pressure-controlling agent. 8. The pharmaceutical composition for application to the mucosa according to claim 7, wherein said osmotic pressure-controlling agent is a salt. 9. The pharmaceutical composition for application to the mucosa according to claim 7, wherein said osmotic pressure-controlling agent is sodium chloride. 10. The pharmaceutical composition for application to the mucosa according to claim 7, wherein said osmotic pressure-controlling agent is a water-soluble sugar. 11. The pharmaceutical composition for application to the mucosa according to claim 7, wherein said osmotic pressure-controlling agent is glucose. 12. The pharmaceutical composition for application to the mucosa according o claim 1 or 3, wherein said water-insoluble and/or low water soluble substance is a cellulose. 13. The pharmaceutical composition for application to the mucosa according to claim 12, wherein said cellulose is crystalline cellulose. 14. The pharmaceutical composition for application to the mucosa according to claim 1 or 3, wherein said one or more water-insoluble and/or low water soluble substance is present as solid particles in an aqueous medium. 15. The pharmaceutical composition for application to the mucosa according to claim 1 or 3, wherein said one or more water-insoluble and/or low water soluble substance is dispersed as solid particles in an aqueous medium. 16. The pharmaceutical composition for application to the mucosa according to claim 1 or 3, further comprising a water-soluble polymer substance. 17. The pharmaceutical composition for application to the mucosa according to claim 16, wherein said water-soluble polymer is one or more selected from the group consisting of alginic acid, polyethylene glycol, glycerin, polyoxyethylene polyoxypropylene glycol, propylene glycol, pectin, low methoxyl pectin, guar gum, gum arabic, carrageenan, methyl cellulose, carboxymethyl cellulose sodium, xanthan gum, hydroxypropyl cellulose, and hydroxypropyl methyl cellulose. 18. The pharmaceutical composition for application to the mucosa according to claim 16, wherein said water-soluble polymer is carboxymethyl cellulose sodium. 19. The pharmaceutical composition for application to the mucosa according to claim 16, wherein said water-soluble polymer is xanthan gum. 20. The pharmaceutical composition for application to the mucosa according to claim 16, wherein said water-soluble polymer is hydroxypropyl methyl cellulose. 21. The pharmaceutical composition for application to the mucosa according to claim 16, wherein the combination of said water-insoluble substance and water-soluble polymer is crystalline cellulose carmellose sodium. 22. The pharmaceutical composition for application to the mucosa according to claim 1 or 3, further comprising a surfactant. 23. The pharmaceutical composition for application to the mucosa according to claim 22, wherein said surfactant is polysorbate 80. 24. The pharmaceutical composition for application to the mucosa according to any of claim 1 or 3, wherein said medicament is a water-soluble medicament. 25. The pharmaceutical composition for application to the mucosa according to any of claim 1 or 3, wherein said medicament is a liposoluble medicament. 26. The pharmaceutical composition for application to the mucosa according to claim 1 or 3, wherein said mucosa is nasal mucosa. 27. The pharmaceutical composition for application to the mucosa according to claim 3, wherein said hemostatic agent is one or more selected from the group consisting of tranexamic acid, epsilon aminocaproic acid, carbazochrome, carbazochrome sulfonate, carbazochrome sodium sulfonate, phytonadione, etamsylate, monoethanol amine oleate, thrombin, hemocoaglase, and adrenochrome monoaminoguanidine mesilate. 28. The pharmaceutical composition for application to the mucosa according to claim 3, wherein the agent other than said hemostatic agent is one or more selected from the group consisting of an antiallergic agent, an antihistamic agent, an anticholinergic agent, a steroid, a vaccine, and a substance for gene therapy, and the mucosa is nasal mucosa. 29. The pharmaceutical composition for application to nasal mucosa according to claim 28, wherein the agent other than said hemostatic agent is a steroid.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.